Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03245749

Enrollment

374

Registered

2017-08-10

Start date

2003-06-30

Completion date

2006-03-31

Last updated

2021-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma Omega-3 Status

Keywords

omega-3 status, blood lipids, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA)

Brief summary

The purpose of this study is to investigate the effect of habitual oily fish intake, sex, age, BMI, and APOE genotype on plasma long chain n-3 fatty acid composition.

Detailed description

The marine long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial to cardiovascular and cognitive health and the concentration of EPA and DHA present in blood and tissue lipids is positively correlated with these effects. As a result, national and global authorities recommend regular consumption of oily fish in order to provide approximately 500 mg EPA+DHA per day in a healthy population. However, the associations between EPA and DHA intake and blood and tissue status, and therefore physiological benefits, are highly variable and the factors influencing this heterogeneity are not well understood. This study aims to investigate the effect of habitual oily fish intake as well as sex, age, BMI, and Apolipoprotein E (APOE) genotype on LC n-3 PUFA status in plasma phosphatidylcholine, non-esterified fatty acids, cholesteryl esters and triacylglycerols in order to obtain greater knowledge of the determinants of LC n-3 PUFA status with the potential to develop more robust, and perhaps subgroup specific, recommendations for EPA and DHA intake.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Exclusion criteria

* Diagnosed endocrine dysfunction including diabetes * Fasting glucose concentration \> 6.5 mmol/L * Myocardial infarction in the previous 2 years * The use of medication that may interfere with lipid metabolism * Fasting total cholesterol of \> 8.0 mmol/L * TG of \> 3.0 mmol/L * Currently following a weight loss diet * Taking n-3 fatty acid supplements

Design outcomes

Primary

Measure	Time frame	Description
Plasma long chain n-3 polyunsaturated fatty acid concentrations	Baseline	Concentrations of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) in plasma phosphatidylcholine, non-esterified fatty acids, cholesteryl esters and triacylglycerols

Secondary

Measure	Time frame	Description
APOE genotyping	Baseline	APOE genotype determined from blood sample
Anthropometric measurements	Baseline	Height and weight to determine BMI

Countries

United Kingdom

Outcome results